JPRN-UMIN000019918已完成2 期
Efficacy and safety of lenalidomide and dexamethasone as consolidation therapy and lenalidomide as maintenance therapy after autologous stem cell transplantation for newly diagnosed multiple myeloma - Efficacy and safety of lenalidomide and dexamethasone as consolidation therapy and lenalidomide as maintenance therapy after autologous stem cell transplantation for newly diagnosed multiple myeloma (GHSG MM-02)
Gifu University Hospital0 个研究点目标入组 20 人开始时间: 2015年11月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 71years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
不适用
Safety and efficacy of lenalidomide, dexamethasone, and clarithromycin therapy in Japanese patients with multiple myeloma, a phase I/II studyMultiple MyelomaJPRN-UMIN000007918ara Hospital Kinki University School Of Medicine32
进行中（未招募）
1 期
The combination of Lenalidomide and Dexamethasone with or without intensification by high-dose Melphalan in the treatment of multiple myelomaprimary treatment of multiple myeloma patients of age 60 till 75 yearsMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2008-004083-39-DEGMIHO Gesellschaft für Medizinische Innovation – Hämatologie und Onkologie mbH348
进行中（未招募）
不适用
SALVAGE TREATMENT WITH LENALIDOMIDE AND DEXAMETHASONE (LEN-DEX) IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL) - NDTreatment of patients with MCL relapsed or refractory to at least one line of chemotherapy, not eligible for or relapsed after more intensive treatments.MedDRA version: 9.1Level: LLTClassification code 10061275Term: Mantle cell lymphomaEUCTR2008-000044-14-ITIIL INTERGRUPPO ITALIANO LINFOMI ONLUS
招募中
不适用
ow dose of lenalidomide and dexamethasone therapy for eldery multiple myelomaRefractory or relapsed symptomatic multiple myelomaJPRN-UMIN000008918ishiwaki municipal hospital26
进行中（未招募）
1 期
Evaluation of Ixazomib, Lenalidomide, Dexamethasone in Newly Diagnosed Multiple Myeloma Patients eligible for High Dose TherapyEUCTR2014-003467-37-FRCHU de Toulouse46